-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Thinking, communicating, summarizing, and seeking development are the driving forces for the development of medicine, and they are also the habits
that doctors in the field of blood have adhered to for decades.
Although there was a pre-epidemic, it could not resist the pace
of their exchanges and discussions.
On November 10, 2022, the "25th National Congress of Clinical Oncology, 2022 CSCO Academic Annual Conference, 10th CSCO Leukemia and Lymphoma Expert Committee Academic Conference, 7th Anti-leukemia and Lymphoma International Summit Forum and CSCO Leukemia Leukemia and Leukemia" hosted by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee and CSCO Lymphoma Expert Committee, and hosted by Harbin Institute of Hematological Oncology and Peking University Cancer Hospital were held by Harbin Institute of Hematological Oncology and Peking University Cancer Hospital & Lymphoma Expert Committee Tour - Harbin Station" officially kicked off
.
In recent years, the treatment demand for leukemia and lymphoma patients in China has been increasing, in order to promote the further improvement of the diagnosis and treatment level of leukemia and lymphoma, the conference has set up a special session for leukemia and lymphoma, inviting many domestic experts in the field of blood to discuss cutting-edge progress
.
The highlights of Leukemia & Lymphoma Session 3 are compiled below for readers
.
Session1
The first session was chaired by Professor Wang Jishi of Guizhou Institute of Hematology and Professor Wang Xiaopei of Peking University Cancer Hospital
.
Professor Wang Jishi and Professor Wang Xiaopei presided
Professor Cai Qingqing gave a wonderful report
Professor Cai Qingqing from Sun Yat-sen University Cancer Hospital shared the progress
of r/r DLBCL treatment.
r/r DLBCL is the most common subtype of lymphoma, and although the prognosis has improved with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), treatment is still limited, and the median overall survival (OS) of patients with high-risk r/r DLBCL is only 7 months
.
According to a number of research results, single or combination therapy such as histone deacetylase, BTK and other small molecule targeted drugs, monoclonal antibodies, bispecific antibodies (CD20×CD3), antibody conjugates (CD79b conjugates) and other single or combination therapies for r/r DLBCL patients have certain efficacy and controllable
safety.
CAR-T cells have achieved significant efficacy
in patients with second-line r/r DLBCL and primary or secondary central nervous system lymphoma.
Prognostic classification of myelodysplastic syndrome (MDS).
Professor Xiao Zhijian gave a wonderful report
Professor Xiao Zhijian, Hospital of Hematology, Chinese Academy of Medical Sciences
, published the prognostic classification of MDS.
In recent years, many types of MDS prognostic scoring systems have emerged for clinical selection, but due to incomplete inclusion of considerations, there is still no prognostic classification scoring system that can comprehensively assess
the prognosis of patients.
In the future, when evaluating the prognosis of MDS patients, it is necessary not only to evaluate the patient's hematological examinations, but also to include the patient's age, molecular genetic characteristics, comorbidities, financial ability, medical insurance status and other aspects for comprehensive assessment
.
Professor Wang Jishi and Professor Wang Xiaopei commented that the two reports respectively sorted out a number of clinical studies of r/r DLBCL, and summarized the current development status of r/r DLBCL and the promising future drug development direction; According to the current MDS prognostic score, the development of the future MDS prognostic scoring system is proposed, and the future clinical diagnosis and treatment of DLBCL and MDS are
guided.
The second session was chaired by Professor Qiu Lugui from the Hematology Hospital of the Chinese Academy of Medical Sciences and Professor Ren Hanyun from Peking University First Hospital
.
Professor Qiu Lugui and Professor Ren Hanyun presided
Professor Feng Ru gave a wonderful speech
Professor Feng Ru from Nanfang Hospital of Southern Medical University shared the progress
of r/r NHL treatment.
In the treatment of r/r follicular lymphoma (FL), bispecific antibodies, EZH2 inhibitors, zebratinib combined with obinutumab have achieved significant efficacy.
In the treatment of r/r mantle cell lymphoma (MCL), non-covalent BTK inhibitors LOXO-305 and ROR1 monoclonal antibody combined with ibrutinib significantly improved the efficacy.
In the treatment of r/r chronic lymphocytic leukemia (CLL), LOXO-305 also has a significant effect; And the FDA has approved the application of CAR-T therapy in r/r FL and r/r MCL; In addition, the new highly selective PI3Kδ inhibitor is the hope
for the treatment of r/r lymphoma in the future because of its wide coverage of the population, significant efficacy and safety.
Professor Jiang Qian gave a wonderful report
Professor Jiang Qian from Peking University People's Hospital shared the clinical features and patient-reported outcomes
of young MPN patients.
The incidence of young MPN in China is higher than that in Western countries, and the clinical manifestations are more headache onset, less thrombosis, low JAK2 mutation rate, high CLAR mutation rate, low HMR mutation ratio, although the symptom burden is slightly light, the physical health is good, but the mental health is poor, the treatment satisfaction is low, the negative impact of disease, treatment or examination on life is greater, and the problem of economic difficulty is prominent and needs more attention
.
Professor Zhang Xi gave a wonderful speech
Professor Zhang Xi of Xinqiao Hospital of Army Medical University shared the relevant content
of lymphoma immunotherapy.
The treatment effect of lymphoma in China is still lower than that of European and American countries, and more effective treatment strategies
are urgently needed.
Professor Zhang Xi elaborated on the four aspects of immunotherapy into immune attack drugs, immune modulatory/enhanced drugs, immune attack cell drugs, and immunotherapy strategies, and proposed that the early intervention of new drugs and targeted drugs may improve the efficacy of patients, and how to select and combine effective and accurate treatment plans in the future is an urgent clinical problem to be solved, and more clinical research is needed for further exploration
.
Professor Qiu Lugui and Professor Ren Hanyun commented that thanks to the wonderful reports brought by the experts, it can be seen from the three reports that many new drugs for r/r NHL have emerged in recent years, and a number of studies have shown that different immunotherapies or immunotherapy combined with chemotherapy can improve the survival of
lymphoma patients.
Young MPN patients are a rare group, and more attention needs to be paid to the diagnosis and treatment status and clinical needs
of such patients.
The third session was chaired by Professor Qiu Lin of Harbin Institute of Hematology and Oncology and Professor Lai Yongrong of the First Affiliated Hospital of Guangxi Medical University
.
Professor Qiu Lin and Professor Lai Yongrong presided
Professor Shi Yuankai gave a wonderful report
evaluating the safety and efficacy of MIL62 injection combined with orelabrutinib tablets in the treatment of r/r B-NHL.
The results showed that among the 30 DLBCL patients, the primary resistant patients were 51.
6%, the objective response rate (ORR) was 56.
7%, the median progression-free survival (PFS) was 5.
8 months, the median follow-up time was 15.
8 months, and the median OS had not yet been reached
.
In 20 patients refractory to rituximab, the ORR was 50%, the median PFS was 5.
7 months, and the median OS had not been reached
.
A total of 43 patients were included in the safety analysis, and the incidence of adverse events (TEAEs) during ≥ 3 treatment period was 46.
5%, the incidence of treatment-related adverse events (TRAEs) in grade ≥ 3 was 37.
2%, the rate of serious adverse events (SAEs) was 32.
6%, the incidence of treatment-related SAEs was 25.
6%, and no treatment-related deaths
occurred.
A Phase I study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of the BCL-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies: preliminary data
Professor Li Caixia gave a wonderful speech
Professor Li Caixia of the First Affiliated Hospital of Soochow University shared preliminary data from a phase I study evaluating the safety, tolerability, pharmacokinetics and preliminary antitumor activity of the BCL-2 inhibitor BGB-11417 in adult patients with mature B-cell malignant tumors, showing that among all 31 patients with known tumor efficacy of BGB-11417 monotherapy, 4 NHL patients and 5 CLL/SLL patients achieved remission and were well tolerated.
and AE did not increase
with increasing dose.
By the end of the data, the maximum tolerated dose (MTD) had not been reached for each dose-climbing cohort, and the study was still recruiting patients
.
Professor Li Junying gave a wonderful speech
Professor Li Junying of Union Hospital of Huazhong University of Science and Technology brought the introduction and data review of LAUNCH research, Professor Li Junying pointed out that LAUNCH is a multicenter, open-label, phase II study to explore the treatment of r/r MM with celiniso, dexamethasone combined with chemotherapy, the ORR reached 55.
6%, the median remission time was 2 months, and the front line (previous treatment ≤ 3 lines) was shown after analyzing the characteristics of the patients.
Patients with high-risk cytogenetics appear to benefit more from treatment, with limited benefit in patients with extramedullary disease or prior exposure to cyclophosphamide and liposomal doxorubicin, and further observation
is required.
Professor Cao Ruolan of Hunan Cancer Hospital
Professor Cao Ruolan of Hunan Cancer Hospital shared the efficacy and safety data
of setipa, orelabrutinib, methotrexate with or without rituximab regimen (TOM±R) in the treatment of CNSL.
Among the 13 patients included in the study, ORR was 92.
31%, CR 53.
85%, most TRAE was grade 1-2, and grade 3 TRAE was mainly hematologic toxicity
.
TOM±R is expected to become a new option
for the clinical treatment of CNSL patients.
Anti-lymphoma effect of novel BAFF-R monoclonal antibody (ESG-206) combined with BTK inhibitor zebratinib on DLBCL PDX model
Professor Cao Jiaowu gave a wonderful report
Professor Cao Jiaowu of Peking University Cancer Hospital shared the anti-lymphoma effect of the novel BAFF-R monoclonal antibody (ESG-206) combined with the BTK inhibitor zebratinib on the DLBCL PDX model
.
The results suggest that BAFF-R is highly expressed in B-NHL and PDX models, which is a promising new therapeutic target, BTK inhibitors can effectively enhance the ADCC effect of ESG-206, and the combination of the two drugs can effectively reduce the tumor burden
of DLBCL PDX models.
Professor Qiu Lin and Professor Lai Yongrong commented that the experts brought five clinical studies for new drugs or new treatment options, each of which was clearly designed and rigorous, and the results showed significant efficacy, and looked forward to each study expanding the sample size, completing follow-up trials, and benefiting more patients
as soon as possible.
Professor Qiu Lin concluded that many experts in the field of hematological oncology benefited greatly from the cutting-edge progress and recent research results of various types of leukemia and lymphoma, and looked forward to the joint efforts of all colleagues in the future to bring the diagnosis and treatment of leukemia and lymphoma in China to a new level
.
Disclaimer: This platform is designed to deliver more medical information
to healthcare professionals.
The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
.
The content published by this platform does not mean that it agrees with its description and views
.
If copyright issues are involved, please contact us and we will deal with
it as soon as possible.
Click to read the original article to see more conference videos
